S100A10 and ovarian carcinoma: Moreover, it was shown that ovarian cancer patients with high expression of cytoplasmic S100A10 and stromal Annexin A2 have a 3.4-fold increased risk of progression and a 7.9-fold higher risk of cancer-related death [150].